Evidence map›Paper›PMID 40356311›Full record

ArticleHuman gene therapy2025

Halting Recombinant Adeno-Associated Virus Transgene Expression Using mRNA-Lipid Nanoparticle-Delivered Meganucleases.

Rubens Tavora, Lizhou Zhang, Mai H Tran, Hao Li, Dan O'Hagan, Andi Pan, Lorenzo Barrett, Joseph A Jablonski, Sonia Mediouni, Alexander Lopez and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human gene therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rubens TavoraDepartment of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, Florida, USA.
Lizhou ZhangDivision of Infectious Disease, Boston Children's Hospital, Boston, Massachusetts, USA.
Mai H TranDivision of Infectious Disease, Boston Children's Hospital, Boston, Massachusetts, USA.
Hao LiThe Skaggs Graduate School of Chemical and Biological Sciences, The Scripps Research Institute, Jupiter, Florida, USA.
Dan O'HaganDepartment of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, Florida, USA.
Andi PanThe Skaggs Graduate School of Chemical and Biological Sciences, The Scripps Research Institute, Jupiter, Florida, USA.
Lorenzo BarrettDepartment of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, Florida, USA.
Joseph A JablonskiDepartment of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, Florida, USA.
Sonia MediouniDepartment of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, Florida, USA.
Alexander LopezDepartment of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, Florida, USA.
Zachary ComellaDepartment of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, Florida, USA.
Charles BaileyDivision of Infectious Disease, Boston Children's Hospital, Boston, Massachusetts, USA.
Hyeryun ChoeDivision of Infectious Disease, Boston Children's Hospital, Boston, Massachusetts, USA.
Michael FarzanDivision of Infectious Disease, Boston Children's Hospital, Boston, Massachusetts, USA.
Susana T ValenteDepartment of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, Florida, USA.ORCID 0000-0002-7854-7554

Funding

HOPE - HIV Obstruction by Programmed EpigeneticsUM1AI164559 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI Lishomwa C Ndhlovu, Melanie Maria Ott · 2021 to 2026
$32.2M
Mode of action of a new Tat HIV-1 inhibitorR01AI097012 · NIAID · UNIVERSITY OF FLORIDA · PI VALENTE, SUSANA T · 2012 to 2022
$7.5M
Evaluation of didehydro-Cortistatin A as a block-and-lock agent for a functional HIV cure in a macaque modelR01AI167732 · NIAID · UNIVERSITY OF FLORIDA · PI David T Evans, Susana T Valente · 2021 to 2026
$4.3M
Exploration of novel block-and-lock agents alone and in combination for HIV remission in humanized miceR01AI177327 · NIAID · UNIVERSITY OF FLORIDA · PI J. Victor Garcia-Martinez, Susana T Valente · 2023 to 2026
$3.5M
Identification and characterization of chromatin regulators of HIV-1 latencyR61AI140439 · NIAID · SCRIPPS FLORIDA · PI VALENTE, SUSANA T · 2018 to 2020
$2.8M
Host factors regulating HIV latency and reactivationR37AI165137 · NIAID · UNIVERSITY OF FLORIDA · PI Susana T Valente · 2022 to 2026
$2.0M
Therapeutic Disruption of HIV Transcription by HIV-1 Tat Protein-Degrading MoleculesR01AI194820 · NIAID · UNIVERSITY OF FLORIDA · PI Susana T Valente · 2025 to 2026
$2.0M
Identification and characterization of chromatin regulators of HIV-1 latencyR33AI140439 · NIAID · UNIVERSITY OF FLORIDA · PI VALENTE, SUSANA T · 2021 to 2022
$1.8M
NIAID NIH HHS R01 AI097012NIAID NIH HHS R01 AI167732NIAID NIH HHS R01 AI177327NIAID NIH HHS R01 AI194820NIAID NIH HHS R33 AI140439NIAID NIH HHS R37 AI165137NIAID NIH HHS R61 AI140439NIAID NIH HHS UM1 AI164559
6 · The paper itself

Abstract

Recombinant adeno-associated virus (rAAV) vectors are increasingly preferred for

Indexed as

DependovirusEndonucleasesNanoparticlesRNA, MessengerTransgenesGene ExpressionGenetic TherapyGenetic VectorsHEK293 CellsHumansLipidsLiposomesEndonucleasesLipid NanoparticlesLipidsLiposomesRNA, Messengergene therapymeganucleasesmRNA-loaded lipid nanoparticlesrecombinant adeno-associated virustransgene

Identifiers

PMID40356311
PMCPMC12171709

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.